• Kura Oncology highlighted Phase 1a FIT-001 data for darlifarnib with cabozantinib in advanced RCC, supporting continued combination development.
• Cabozantinib-naive clear-cell RCC showed ORR of 33%-50% across dose cohorts; median PFS was 13 months.
• Across 72 treated RCC patients, grade ≥3 treatment-emergent adverse events occurred in 76%; neutropenia was 38%.
• Cash and investments totaled $580.8 million as of 3/31/26; management also cited $180 million in anticipated payments.
• Phase 1b expansion is enrolling cabozantinib-naive clear-cell RCC; a Phase 1a escalation with daraxonrasib in second-line or later PDAC is planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.